Literature DB >> 22366800

A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy.

Bengt Skoog1, Björn Runmarker, Stefan Winblad, Sven Ekholm, Oluf Andersen.   

Abstract

Multiple sclerosis may have a non-progressive symptomatology for decades; however, it is not clear whether the disease activity may abate completely. We identified a cohort of patients, resident in Gothenburg at the time of disease onset, between the years 1950-64 (n = 307). These geographical and temporal restrictions, along with favourable conditions for a 'spider' epidemiological study, were optimal for an unbiased selection; this 15-year incidence cohort was essentially followed prospectively for 37-59 years after onset. The shortest follow-up time for patients without primary or secondary progression was 45 years. For patients with an initial relapsing-remitting course and multiple sclerosis diagnosis according to the Poser criteria (n = 202), the probability of non-progressive disease after 40 years was 22% (standard error 3.0%), and after 50 years it was 14% (standard error 3.2%). For attack onset including patients with possible multiple sclerosis, the corresponding probabilities after 40 and 50 years were 35% (standard error 3.3%) and 28% (standard error 3.5%), respectively. At the last follow-up in 2009-10, when patients reached the average age of the Swedish population life expectancy, only 13 patients from the multiple sclerosis diagnosis cohort, according to the Poser criteria, remained alive and non-progressive. Their annualized attack frequency diminished with time from 0.29 to 0.015. These patients had been functioning well socially. Nine patients had an Expanded Disability Status Scale score of 0-2.5, and four patients had a score of 3 or 3.5, with deficits dating back to attacks decades ago. Eight patients participated in a complete neuropsychological examination, which showed a slight difference (P < 0.01) concerning verbal memory and executive function compared to an age and socially matched reference group, whereas results for five other cognitive domains were within the normal range. Magnetic resonance images fulfilled the Barkhof-Tintoré criteria for multiple sclerosis in 10 of 11 patients, with conspicuously few subcortical lesions relative to extensive periventricular lesions and lesions extending from the inferior midline aspect of the corpus callosum. Prediction of the non-progressive stage was possible with moderate hazard ratios and low sensitivity. Early features that predicted a non-progressive course were complete remission of the onset attack, low or moderate initial relapse frequency and-when the patients with possible multiple sclerosis were included-dominating afferent symptoms. The clinical disease activity had abated in these 13 patients, with the caveat that transition to secondary progression continued to occur after four decades, albeit with decreasing risk.

Entities:  

Mesh:

Year:  2012        PMID: 22366800     DOI: 10.1093/brain/awr336

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  13 in total

1.  Natural history of multiple sclerosis symptoms.

Authors:  Ilya Kister; Tamar E Bacon; Eric Chamot; Amber R Salter; Gary R Cutter; Jennifer T Kalina; Joseph Herbert
Journal:  Int J MS Care       Date:  2013

2.  Hereditary diffuse leukoencephalopathy with spheroids with phenotype of primary progressive multiple sclerosis.

Authors:  Christina Sundal; Matt Baker; Rosa Rademakers; Oluf Andersen; Virginija Karrenbauer; Marte Gustavsen; Sahl Bedri; Anna Glaser; Kjell-Morten Myhr; Kristoffer Haugarvoll; Henrik Zetterberg; Hanne Harbo; Ingrid Kockum; Jan Hillert; Zbigniew Wszolek
Journal:  Eur J Neurol       Date:  2014-10-13       Impact factor: 6.089

3.  The outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset.

Authors:  Helen Tedeholm; Bengt Skoog; Vera Lisovskaja; Björn Runmarker; Olle Nerman; Oluf Andersen
Journal:  J Neurol       Date:  2015-02-26       Impact factor: 4.849

4.  Disability in multiple sclerosis: a reference for patients and clinicians.

Authors:  Ilya Kister; Eric Chamot; Amber R Salter; Gary R Cutter; Tamar E Bacon; Joseph Herbert
Journal:  Neurology       Date:  2013-02-20       Impact factor: 9.910

Review 5.  Apparent changes in the epidemiology and severity of multiple sclerosis.

Authors:  Nils Koch-Henriksen; Melinda Magyari
Journal:  Nat Rev Neurol       Date:  2021-09-28       Impact factor: 42.937

Review 6.  Definition, prevalence and predictive factors of benign multiple sclerosis.

Authors:  Tatjana Reynders; Miguel D'haeseleer; Jacques De Keyser; Guy Nagels; Marie B D'hooghe
Journal:  eNeurologicalSci       Date:  2017-05-13

7.  The Optimization of Magnetic Resonance Imaging Pulse Sequences in Order to Better Detection of Multiple Sclerosis Plaques.

Authors:  Z Farshidfar; F Faeghi; H R Haghighatkhah; J Abdolmohammadi
Journal:  J Biomed Phys Eng       Date:  2017-09-01

8.  Predictors for Therapy Response to Intrathecal Corticosteroid Therapy in Multiple Sclerosis.

Authors:  Katja Vohl; Alexander Duscha; Barbara Gisevius; Johannes Kaisler; Ralf Gold; Aiden Haghikia
Journal:  Front Neurol       Date:  2019-02-22       Impact factor: 4.003

9.  Impairment and restrictions in possibly benign multiple sclerosis.

Authors:  Laura Melanie Schaefer; Jana Poettgen; Anja Fischer; Stefan Gold; Jan-Patrick Stellmann; Christoph Heesen
Journal:  Brain Behav       Date:  2019-03-18       Impact factor: 2.708

Review 10.  Personalized medicine in multiple sclerosis: hope or reality?

Authors:  Tobias Derfuss
Journal:  BMC Med       Date:  2012-10-04       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.